High Cholesterol Treatment: Statins, PCSK9 Inhibitors, and LDL Targets

The Lower, The Better — Within Reason

Cardiovascular disease remains the world's leading cause of death, and low-density lipoprotein cholesterol (LDL-C) is the causal driver of atherosclerosis. Every 1 mmol/L (approximately 39 mg/dL) reduction in LDL-C reduces major vascular events — heart attack, stroke, cardiovascular death — by approximately 22%, according to the 2010 Cholesterol Treatment Trialists' Collaboration meta-analysis of 170,000 patients. This dose-response relationship holds across a wide range of baseline LDL-C levels and across all major risk subgroups. The evidence base for LDL lowering is among the strongest in all of cardiovascular medicine.

Despite this evidence, only about 55% of American adults with high cardiovascular risk are on lipid-lowering therapy, and of those treated, fewer than half achieve guideline-recommended LDL-C targets. The treatment gap persists due to statin intolerance, prescriber inertia, and patient non-adherence.

LDL-C Targets by Cardiovascular Risk

Statins: Mechanism, Intensity, and Side Effects

Statins competitively inhibit HMG-CoA reductase, the rate-limiting enzyme in the liver's cholesterol synthesis pathway. Reduced intracellular cholesterol triggers upregulation of LDL receptors on hepatocyte surfaces, clearing LDL-C from the bloodstream. Different statins achieve different degrees of LDL reduction:

• High-intensity statins (rosuvastatin 20–40 mg, atorvastatin 40–80 mg): Lower LDL-C by ≥50%
• Moderate-intensity statins (atorvastatin 10–20 mg, rosuvastatin 5–10 mg, simvastatin 20–40 mg): Lower LDL-C by 30–49%
• Low-intensity statins (simvastatin 10 mg, pravastatin 10–20 mg): Lower LDL-C by <30%

Statin-associated muscle symptoms (SAMS) — ranging from mild myalgia to rare rhabdomyolysis — represent the most common reason for discontinuation. In clinical practice, up to 10–20% of patients report muscle symptoms, though nocebo effects account for a substantial portion. The SAMSON trial (2020) elegantly demonstrated this: 90 statin-intolerant patients underwent blinded crossover between atorvastatin and placebo in monthly periods; 90% of muscle symptom burden occurred on both statin and placebo, and 71% of patients tolerated re-introduction with full information after trial completion.

PCSK9 Inhibitors: Expensive but Powerful

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that promotes degradation of LDL receptors on hepatocytes. Higher PCSK9 activity means fewer LDL receptors and higher circulating LDL-C. Naturally occurring loss-of-function mutations in PCSK9 — found in about 2–3% of African Americans — produce LDL-C levels of 40–50 mg/dL and dramatically reduced lifetime cardiovascular event rates, validating the therapeutic target.

PCSK9 inhibitors list at approximately $5,500–6,500 per year in the U.S. after years of restrictive prior authorization policies. Inclisiran, with its twice-yearly dosing, offers a practical adherence advantage for patients who struggle with frequent injections.

Bempedoic Acid and Ezetimibe

Bempedoic acid (Nexletol, approved 2020) inhibits ATP-citrate lyase, an enzyme upstream of HMG-CoA reductase in the cholesterol synthesis pathway. Critically, the drug requires activation by an enzyme present in the liver but absent in skeletal muscle — meaning it produces LDL-C reductions of 18–25% without the myopathy risk associated with statins. The CLEAR Outcomes trial (2023) confirmed its cardiovascular efficacy in statin-intolerant patients, reducing major adverse cardiovascular events by 13%.

Ezetimibe blocks intestinal cholesterol absorption via the NPC1L1 transporter, lowering LDL-C by approximately 18–20% as monotherapy and an additional 24% when added to a statin. The IMPROVE-IT trial demonstrated that adding ezetimibe to simvastatin in post-ACS patients reduced cardiovascular events by an additional 6.4% — confirming that "lower is better" holds even at LDL-C levels already well below 70 mg/dL.

Understanding NNT

Number needed to treat (NNT) contextualizes the absolute benefit of lipid-lowering therapy, which varies by baseline risk. For statins in secondary prevention (very high risk): NNT of approximately 35–50 over 5 years to prevent one major cardiovascular event. In primary prevention in lower-risk individuals, the NNT may exceed 200 over the same period — highlighting the importance of risk stratification before initiating treatment and why blanket population-wide statin prescribing without risk assessment is not guideline-concordant practice.

This article is for informational purposes only. Consult a qualified healthcare professional.